BioSpace News Archive

Gaumard Scientific Co., an industry leader of simulation technology for healthcare education and training, today announced the unveiling of Obstetric MR™ for VICTORIA®, a new mixed reality training solution designed to help learners achieve clinical competency faster and more efficiently

Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointments of Mace Rothenberg, MD, and Lesley Ann Calhoun, CPA, to its Board of Directors.

Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, announced today a multi-target discovery collaboration leveraging Valence’s platform for generative drug design with Servier, a global pharmaceutical company.

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform.

Aspen Surgical Products, Inc., a leader in surgical disposable products, announced the acquisition of BlueMed Medical Supplies, Inc..

Biocom California and the California Life Sciences Association (CLSA) today released data analyzing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.

Nascent Biotech, Inc. (OTCQB:NBIO) , a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Companys lead Monoclonal Antibody (Mab) therapeutic asset

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to 12 new employees.

Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced that its Acorn AI commercial data management technology was used by oncology biopharmaceutical company EUSA Pharma for the U.S. commercial relaunch of SYLVANT (siltuximab).

Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it has reached an agreement with GL Mountrose Investment Two Limited, a company controlled and managed by GL Capital Group (“GL Capital”), to sell its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”),